natera™ | Horizon™ Advanced carrier screening | Panorama™ Next-generation NIPT

Discover more about your growing family

Two types of genetic tests are commonly offered

1 **Carrier screening** is a blood or saliva test performed before or during pregnancy that determines the chances of **passing on an inherited genetic condition** to your child.

Why get carrier screening?

- All of us are carriers of at least one genetic condition.[1] Most carriers are healthy, with no family history, but they are at risk of passing on a genetic condition to their child.
- Carrier screening can help you make informed decisions that could impact your child's health. It tests for genetic conditions that can benefit from early medical care and treatment.

2 **Noninvasive prenatal testing (NIPT)** is a blood test performed during pregnancy that identifies whether **your baby has a higher chance of having certain chromosomal conditions,** such as Down syndrome.

Why choose NIPT?

- NIPT is a safe, noninvasive way to screen your baby for chromosomal conditions as early as nine weeks into your pregnancy.
- NIPT provides substantially fewer incorrect results than maternal serum screening.[2–15]

natera™ | Horizon™ Advanced carrier screening | Panorama™ Next-generation NIPT

What does Horizon™ screen for?

Autosomal Recessive Conditions

- We carry two copies of most of our genes, one inherited from each of our biological parents. Autosomal recessive conditions occur when both copies of the gene pair have a change. A person is a carrier if only one copy of the gene has a change.
- Couples who are carriers of the same genetic condition have a **25% (1 in 4)** chance of having an affected child with each pregnancy.



Examples: Cystic fibrosis and spinal muscular atrophy

X-Linked Conditions

- X-linked conditions occur when the female parent is a carrier.
- A carrier female parent has a **50% (1 in 2)** chance of having an affected male child or carrier female child with each pregnancy.



Example: Duchenne muscular dystrophy

What does Panorama™ screen for?

Condition	PPV*
Trisomy 21 (Down syndrome)	**95%**[17]
Trisomy 18 (Edwards syndrome)	**91%**[17]
Trisomy 13 (Patau syndrome)	**68%**[17]
Monosomy X (Turner syndrome)**	**78%**[17]
Sex chromosome trisomies**	**86.4%**[18]
22q11.2 deletion syndrome (optional)**	**53%**[19]
Four additional microdeletions (optional)†	**5–17%**[20]
Triploidy†	**11%**[21]

Positive Predictive Value (PPV) is the chance that a high risk result means your baby actually has a genetic condition. PPVs apply to singleton, egg donor, gestational carrier, and identical twin pregnancies. For performance for nonidentical twin pregnancies, go to* **natera.com/panorama-tests/test-specs

***Not available for egg donor, gestational carrier, and nonidentical twin pregnancies.*

†For singleton pregnancies only.

Panorama™ NIPT can also identify your baby's sex (optional) .To learn more about these conditions, go to **natera.com/panorama-conditions**

Why choose Horizon™ and Panorama™?

Unmatched support

- Complimentary genetic information sessions before and after testing are available with Natera's board-certified genetic counselors.
- NEVA, Natera's Educational Virtual Assistant, provides easy, 24–7 access to results, education, and guidance on next steps.

What if I get a positive screen or high risk result?

Horizon™ carrier screen and Panorama™ NIPT are **screening tests,** which means that these tests do not make a final diagnosis. A positive screen or a high risk result means that your pregnancy could have a greater chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based on screening results alone.

All medical decisions should be made after discussion with your healthcare provider (HCP) regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.

If you receive a positive Horizon™ carrier screen result, speak with your HCP about whether your partner should also be tested before planning next steps. If you receive a positive Horizon™ carrier screen result or high risk Panorama™ NIPT result, speak with your HCP to determine next steps, such as genetic counseling, detailed ultrasound, and the option of diagnostic testing.

Lola's story

Lola was born with spinal muscular atrophy, a rare hereditary condition that occurs when both parents are carriers of a changed or missing gene.

Scan to learn how carrier screening can make a difference.

Advanced technology

- Horizon™ and Panorama™ are the most widely used carrier screen and NIPT.[22] Just one blood draw is required for both tests. Horizon™ provides comprehensive carrier screening using the latest technology, including next-generation sequencing. Panorama™ is the only NIPT that can tell the difference between your and your baby's DNA.[2–15] This helps avoid some sources of incorrect results.[23] Panorama™ NIPT also has zero fetal sex errors in published clinical validations.[2–15]

Affordable testing

- Natera is an in-network provider with most major health plans. The cost of our tests varies according to the tests selected and your specific insurance coverage. Most patients receiving reproductive care meet their deductible.
- If you haven't met your deductible, what you pay will go towards that amount, after which insurance begins to contribute to your care.
- If your insurance plan denies the claim, you will be eligible for a discounted self pay price.
- Horizon™ and Panorama™ are typically billed as separate tests, and they can be ordered separately.
- Visit **my.natera.com/billing** to learn more.

What can Horizon™ tell me?

Horizon™ Advanced Carrier Screen looks at **your DNA** to screen for inherited genetic conditions, such as cystic fibrosis, spinal muscular atrophy, and fragile X syndrome.[16] The test determines **your chance of having a child with these or other conditions.** Results are typically available in two weeks.

Scan to view the conditions screened by Horizon™.

What can Panorama™ tell me?

Unlike the conditions screened for by Horizon™ carrier screen, Panorama™ Noninvasive Prenatal Test (NIPT) screens for **genetic changes that happen by chance and are not typically inherited.**

During your pregnancy, your blood contains DNA from both you and your baby's placenta. Panorama™ NIPT looks at the **placental DNA** to see if there is evidence of certain chromosomal conditions, such as Down syndrome, that could affect your baby's health.

Results are typically available in one week. You will receive a personalized risk report that indicates if your pregnancy is at high or low risk for the screened conditions.

Scan for detailed test performance information on Panorama™.

Want to learn more? Text the following keywords to 636363

COMBO to learn more about the tests

Watch a short informational video about Horizon™ carrier screen and Panorama™ NIPT.

SESSION for genetic information sessions

Schedule a complimentary phone call with a board-certified genetic counselor before or after your tests.

COVERAGE for information on coverage & pricing

Natera is an in-network provider with most health plans. Check your coverage, receive a pretest estimate, and learn if you qualify for our Compassionate Care Program.

DRAW for blood draw services

Once you have your test kit, find a local blood draw site or find other blood draw solutions.

If you have any questions on the Horizon™ and Panorama™ tests or how to get tested, call us at **844.778.4700**

Texting 636363 will provide you with a single text in response to each keyword from our Patient Ed program. Msg&Data Rates May Apply. You can get additional information by texting HELP to 636363 and unsubscribe by texting STOP to 636363. For terms & conditions, please go to: natera.com/terms/. For Natera's privacy policy, please go to: natera.com/privacy/

References

1. Bell et al. Sci Transl Med. 2011 Jan; 3(65):65ra4.
2. Nicolaides et al. Prenat Diagn. 2013 Jun; 33(6):575-9.
3. Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8.
4. Ryan et al. Fetal Diagn Ther. 2016; 40(3):219-223.
5. Stokowski et al. Prenat Diagn. 2015 Dec; 35(12):1243-6.
6. Jones et al. Ultrasound Obstet Gynecol. 2018 Feb; 51(2):275-6.
7. Palomaki et al. Genet Med. 2011 Nov; 13(11):913-20.
8. Palomaki et al. Genet Med. 2012 Mar; 14(3):296-305.
9. Porreco et al. Am J Obstet Gynecol. 2014 Oct; 211(4):365.e1-12.
10. Mazloom et al. Prenat Diagn. 2013 Jun; 33(6):591-7.
11. Sehnert et al. Clinical Chemistry. 2011 Jul; 57(7):1042–9.
12. Bianchi et al. Obstet Gynecol. 2012 May; 119(5):890-901.
13. Bianchi et al. N Engl J Med. 2014 Feb; 370(9):799-808.
14. Verinata Health. Analytical validation of the Verifi prenatal test, 2012.
15. Dar et al. Am J Obstet Gynecol. Epub prior to publication. https://doi.org/10.1016/j.ajog.2022.01.019
16. Westemeyer et al. Genet Med. 2020; 22(8):1320-28.
17. DiNonno et al. J Clin Med. 2019 Aug 26;8(9):1311. doi:10.3390/jcm809131.
18. Martin et al. 25th International Conference on Prenatal Diagnosis and Therapy Meeting; June 6-8, 2021.
19. Dar et al. Am J Obstet Gynecol. 2022 Jul;227(1):79.e1-79.e11.
20. Martin et al. Clin Genet. 2018 Feb;93(2):293-300.
21. Kantor et al. Prenat Diagn. 2022;42:994–999.
22. Internal market research and claims data analysis using Definitive Healthcare data set. 2021.
23. ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct; 136(4):859-867.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

PAN_HOR_PT_BR_20221202_NAT-801864

natera™